logo
Plus   Neg
Share
Email

AstraZeneca: Imfinzi Shows Improved, Durable Responses In Extensive-stage SCLC

AstraZeneca (AZN.L,AZN) said Imfinzi (durvalumab) significantly improved overall survival in patients with previously-untreated extensive-stage small cell lung cancer. The detailed results from the Phase III CASPIAN trial were presented at the Presidential Symposium of the IASLC 2019 World Conference on Lung Cancer. The safety and tolerability of Imfinzi in combination with SoC etoposide and platinum-based chemotherapy was consistent with prior trials.

Jose´ Baselga, Executive Vice President, Oncology R&D said: "We are encouraged to see more than a third of small cell lung cancer patients treated with Imfinzi plus chemotherapy alive at the 18-month landmark, which is remarkable given the aggressive nature of the disease."

Imfinzi is approved in the curative-intent setting of unresectable, Stage III non-small cell lung cancer after chemoradiotherapy in 49 countries.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The United Auto Workers at General Motors will remain on strike until ratification of a new four-year labor contract, the union said on Thursday. GM's proposed agreement includes an $11,000 ratification bonus to workers, wage increases of 4 percent throughout the four-year contract, no increases in health care costs; and a path to permanent worker status within four years or less. Streaming giant Netflix Inc. (NFLX) announced that it secured rights to Jeff Smith's critically acclaimed comic book series BONE. Netflix said it plans to develop an animated kids series based on BONE that follows the iconic Bone cousins on an adventure through a vast, uncharted desert and into a... Swedish luxury auto maker Volvo Cars unveiled its first fully electric car, the XC40 Recharge. The XC40 Recharge is a part of the electrified car portfolio that Volvo plans to introduce under the new 'Recharge' sub-brand. The company said it plans to launch a fully electric car every year over the...
Follow RTT
>